Acridine衍生物,特別是9-anilinoacridines可以嵌入DNA並且抑制哺乳動物的拓樸異構酶(TOPO II),已被廣泛的研究作為化療試劑。而其中4’-(9-acridinylamino)methanesulfonyl-m-anisidine (amsacrine, m-AMSA)由於其不錯的活性,在臨床上已成為血癌(leukemia)和淋巴腺癌(lymphoma)藥物。Acridine的等價異構物2-苯基喹啉可視為具有抗腫瘤2-苯基奈骨架aza的類似物,許多這一類的化合物具有抗腫瘤的活性。因此我們合成出一系列2-苯基-8羥基喹啉衍生物並探討其抗癌的生物活性,這一類的結構是屬於常見的2-苯基奈的型式,而omime、methyloxime及carboxamide衍生物已被合成出,我們預期oxime(氫鍵的提供者)和methyloxime(氫鍵的接受者)能夠與DNA形成氫鍵並與2-苯基-8-羥基喹啉衍生物互相作用。
Acridine derivatives, especially 9-anilinoacridines have been extensively studied as potential chemotherapeutic agents due to their capability of intercalating DNA leading to the inhibition of mammalian topoisomerase II. Among them, 4’-(9-acridinylamino)methanesulfonyl-m-anisidine (amsacrine, m-AMSA), has been specifically relevant and become a useful clinical drug for the treatment of leukemia and lymphoma. The repleacement of acridine with its isosteric 2-phenylquinoline ring was considered as an aza-analogue of antitumor 2-phenylnaphthalene skeleton. A number of these compounds have antitumor activities. Thus, we have synthesized certain 2-phenyl-8-hydroxyquinoline derivatives and evaluted their anticancer activities. The oxime, methyloxime, carboxamide and C-8 hydroxy derivatives were also synthesized for evaluation. We expected that oxime (H-bonding donor) and methyloxime (H-bonding accepotor) will form hydrogen bonding with DNA molecule during the interaction process of 2-phenyl-8-hydroyquinoline derivatives.